Skip to content
MedsAcross

Medicine

Sovuna 200 mg tablet

Hydroxychloroquine · Oral · ANI Pharmaceuticals
Available on requestPrescription onlyUS FDA

Sovuna 200 mg tablet is a prescription medicine containing Hydroxychloroquine for oral use, marketed by ANI Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at room temperature between 20°C and 25°C (68°F and 77°F), allow…

Key facts

Active ingredient (INN)
Hydroxychloroquine
Brand
Sovuna
Strength
200 mg
Dosage form
Tablet
Route
Oral
Packs
30 tablets, 100 tablets
Marketing authorisation holder
ANI Pharmaceuticals
Manufacturer
ANI Pharmaceuticals
Origin register
US FDA, United States
Storage
Store at room temperature between 20°C and 25°C (68°F and 77°F), allow excursions between 15°C and 30°C (59°F and 86°F). Storage Dispense in a tight, light-resistant container as defined in the USP/NF.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
P01BA02 Hydroxychloroquine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
15 September 2023
Identifiers
RxCUI 979092, 2569283, 2665282 +1DailyMed set ID dd441154-b196-4d4c-bc56-2e37f345ef8dNDC 70954-804Application NDA214581

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
30 tablet, film coated in 1 bottle70954-804-10ANI Pharmaceuticals15 September 2023
100 tablet, film coated in 1 bottle70954-804-20ANI Pharmaceuticals15 September 2023

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 18 April 1955Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Hydroxychloroquine 200 mg tablet.

Compare all 2

Other strengths and forms of Hydroxychloroquine

Clinical summary

Hydroxychloroquine is an antimalarial indicated for the treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients, among other approved uses. MedsAcross supplies Hydroxychloroquine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Hydroxychloroquine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Sovuna 200 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.